{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Frequency of toxicities was reported by type and grade according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).","groups":[{"description":"Romidepsin 12 mg/m2 d.1,8, 15 + Gemcitabine 800 mg/m2 d.1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 d. 1, 15 to PD\n\nRomidepsin, Gemcitabine: Romidepsin 12 mg/m2 d.1,8, 15 for 6 cycles + Gemcitabine 800 mg/m2 d.1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 d. 1, 15 to PD.","id":"OG000","title":"Romidepsin, Gemcitabine"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Safety - Frequency of Toxicities Grade 3 and 4","type":"SECONDARY","unitOfMeasure":"events"}